TRANSGENE

🇫🇷France
Ownership
-
Employees
-
Market Cap
-
Website

Non-investigational Study to Evaluate Adenovirus Serotype 5 (Ad5) Neutralizing Antibodies (nAb) in Patients With Chronic Hepatitis B Virus (HBV) Mono-infection

Not Applicable
Completed
Conditions
First Posted Date
2015-02-04
Last Posted Date
2016-02-02
Lead Sponsor
Transgene
Target Recruit Count
166
Registration Number
NCT02355951

Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2011-06-28
Last Posted Date
2017-01-05
Lead Sponsor
Transgene
Target Recruit Count
222
Registration Number
NCT01383148
Locations
🇩🇪

Universitaetsklinikum Mannheim, Mannheim, Germany

🇭🇺

Orszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, Hungary

🇭🇺

Petz Aladár Megyei Oktató kórház, Győr, Hungary

and more 69 locations

Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients

First Posted Date
2010-01-26
Last Posted Date
2013-08-13
Lead Sponsor
Transgene
Target Recruit Count
140
Registration Number
NCT01055821
Locations
🇩🇪

Hospital, Hannover, Germany

Trial of TG4023 Combined With Flucytosine in Liver Tumors

Phase 1
Completed
Conditions
First Posted Date
2009-09-16
Last Posted Date
2014-07-16
Lead Sponsor
Transgene
Target Recruit Count
16
Registration Number
NCT00978107
Locations
🇫🇷

Hôpitaux Civils de Colmar, Colmar, France

🇫🇷

Institut Paoli Calmette,, Marseille, France

🇫🇷

Hôpitaux Civils de Lyon,, Pierre Benite, France

and more 3 locations

Immunotherapy With TG4040 in Treatment-naïve Patients Chronically Infected With Hepatitis C Virus

Phase 1
Completed
Conditions
First Posted Date
2007-09-14
Last Posted Date
2010-09-03
Lead Sponsor
Transgene
Target Recruit Count
42
Registration Number
NCT00529321
Locations
🇫🇷

Hôpital Henri Mondor, Créteil, France

🇫🇷

Hopital A. Michallon, La Tronche, France

🇫🇷

Hôpital de l'Hôtel Dieu, Nantes, France

and more 3 locations

Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer

First Posted Date
2006-12-25
Last Posted Date
2014-07-16
Lead Sponsor
Transgene
Target Recruit Count
148
Registration Number
NCT00415818
Locations
🇵🇱

Oddział Chemioterapii, Krakow, Poland

🇵🇱

Dolnośląskie Centrum, Wrocław, Poland

🇫🇷

Centre François Baclesse, Caen, France

and more 20 locations

Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma

Phase 2
Completed
Conditions
First Posted Date
2006-11-01
Last Posted Date
2014-07-16
Lead Sponsor
Transgene
Target Recruit Count
13
Registration Number
NCT00394693
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

🇺🇸

Northwestern University Medical School, Chicago, Illinois, United States

🇫🇷

Hopital Lapeyronie, Montpellier, France

and more 3 locations

Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer

Phase 2
Terminated
Conditions
First Posted Date
2002-06-25
Last Posted Date
2006-11-02
Lead Sponsor
Transgene
Target Recruit Count
50
Registration Number
NCT00040170
Locations
🇺🇸

Cleveland Clinic Foundation, Cleveland, Ohio, United States

🇺🇸

Arizona Cancer Center, Tucson, Arizona, United States

🇺🇸

UCLA, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath